Alexandria Pharmaceuticals results, Q1 2026
Net profit, assets, equity and cash flow for Q1 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July. The figures cover the 3 months to 30 September 2025; the comparison is with the same months a year earlier, from the same disclosure.
In short
- Alexandria Pharmaceuticals's net profit for Q1 2026 was about 104 million EGP, up +5.3% from 98.51 million EGP in Q1 2025.
Key lines against the same period a year earlier
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. The figures cover the 3 months to 30 September 2025; the comparison is with the same months a year earlier, from the same disclosure.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy